BioCryst Pharmaceuticals, Inc. (BCRX) Earnings History
Net Loss32 years of earnings data (1994–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
BioCryst Pharmaceuticals, Inc. (BCRX) Earnings Overview
As of June 23, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) reported trailing twelve-month net income of -$458M, reflecting +381.4% year-over-year growth. The company earned $-1.89 per diluted share over the past four quarters, with a net profit margin of 30.2%.
Looking at the long-term picture, BCRX's historical earnings data spans multiple years. The company achieved its highest annual net income of $264M in fiscal 2025, representing a new all-time high.
BioCryst Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACAD ($376M net income, 36.5% margin), BCRX has outperformed on profitability metrics. Compare BCRX vs RARE →
BCRX Earnings vs Peers
Earnings metrics vs comparable public companies
BCRX Historical Earnings Data (1994–2025)
32 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $264M | +396.9% | $341M | $1.21 | 30.2% | 39.0% |
| 2024 | -$89M | +60.8% | -$3M | $-0.43 | -19.7% | -0.6% |
| 2023 | -$227M | +8.3% | -$104M | $-1.18 | -68.4% | -31.3% |
| 2022 | -$247M | -34.3% | -$148M | $-1.33 | -91.2% | -54.8% |
| 2021 | -$184M | -0.7% | -$178M | $-1.03 | -117.1% | -113.1% |
| 2020 | -$183M | -67.9% | -$175M | $-1.09 | -1026.4% | -981.1% |
| 2019 | -$109M | -7.6% | -$99M | $-0.94 | -223.0% | -203.7% |
| 2018 | -$101M | -53.9% | -$94M | $-0.98 | -490.3% | -456.2% |
| 2017 | -$66M | -19.3% | -$57M | $-0.78 | -261.2% | -227.9% |
| 2016 | -$55M | -28.2% | -$49M | $-0.75 | -209.3% | -184.4% |
| 2015 | -$43M | +4.8% | -$39M | $-0.59 | -89.1% | -81.7% |
| 2014 | -$45M | -50.1% | -$46M | $-0.68 | -332.1% | -336.4% |
| 2013 | -$30M | +23.0% | -$31M | $-0.55 | -173.7% | -177.2% |
| 2012 | -$39M | +31.4% | -$34M | $-0.79 | -148.6% | -128.9% |
| 2011 | -$57M | -74.0% | -$50M | $-1.26 | -289.9% | -252.4% |
| 2010 | -$33M | -143.3% | -$33M | $-0.73 | -51.5% | -52.3% |
| 2009 | -$13M | +45.6% | -$14M | $-0.35 | -18.0% | -18.4% |
| 2008 | -$25M | +14.9% | -$27M | $-0.65 | -43.7% | -48.0% |
| 2007 | -$29M | +33.4% | -$32M | $-0.89 | -40.8% | -45.3% |
| 2006 | -$44M | -67.1% | -$47M | $-1.50 | -702.2% | -756.3% |
| 2005 | -$26M | -23.7% | -$27M | $-1.01 | -17185.3% | -17895.2% |
| 2004 | -$21M | -66.2% | -$22M | $-1.00 | -6264.2% | -6456.5% |
| 2003 | -$13M | +25.0% | -$13M | $-0.72 | -777.2% | -777.2% |
| 2002 | -$17M | -239.5% | -$17M | $-0.96 | -954.0% | -932.9% |
| 2001 | -$5M | +56.9% | -$5M | $-0.28 | -44.7% | -44.7% |
| 2000 | -$12M | -118.4% | -$10M | $-0.61 | -349.2% | -296.5% |
| 1999 | -$5M | -10.4% | -$8M | $-0.34 | -212.0% | -324.0% |
| 1998 | -$5M | +54.7% | -$6M | $-0.34 | -75.0% | -93.8% |
| 1997 | -$11M | -37.7% | -$12M | $-0.77 | -1060.0% | -1230.0% |
| 1996 | -$8M | +10.5% | -$8M | $-0.69 | -285.2% | -281.5% |
| 1995 | -$9M | -24.6% | -$9M | $-0.96 | -4300.0% | -4550.0% |
| 1994 | -$7M | - | -$7M | $-1.02 | -985.7% | -971.4% |
Download Data
Export BCRX earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
32+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BCRX — Frequently Asked Questions
Quick answers to the most common questions about buying BCRX stock.
What is BCRX earnings per share (EPS)?
BCRX trailing twelve-month (TTM) diluted EPS is $-1.89, reflecting +381.4% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 1994 to 2025 is available in the table on this page.
What is BioCryst Pharmaceuticals, Inc.'s net income?
BioCryst Pharmaceuticals, Inc. (BCRX) trailing twelve-month net income is $-458M as of 2025. Earnings grew +381.4% year-over-year.
Is BCRX profitable?
BCRX is not currently profitable on a TTM basis, reporting a net loss of $-458M. Net margin is +30.2%. Investors should monitor for a return to profitability.
What is BCRX's earnings growth rate?
BCRX compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 1994 to 2025.
What are BCRX's profit margins?
BioCryst Pharmaceuticals, Inc. net profit margin is +30.2%, operating margin is +39.0%, and gross margin is +97.8%. Above-average net margins reflect strong pricing power and competitive moat. Return on Equity is N/A.
Is BCRX growing earnings?
Yes, BCRX earnings are accelerating — EPS growth of +381.4% exceeds the 5-year CAGR of N/A. TTM net income reached $-458M. Earnings momentum is strengthening.
What was BCRX's best earnings year?
BioCryst Pharmaceuticals, Inc.'s highest annual net income on record is $264M, achieved in fiscal year 2025. Earnings history on this page spans 1994 to 2025 and includes all annual and quarterly figures.
What were BCRX's earnings last quarter?
BCRX's most recent reported quarter was Q1 2026. Net income was $-722M with diluted EPS of $-2.98. For a full breakdown of all quarters, see the quarterly earnings table on this page.